| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate L Dang, DW White, S Gross, BD Bennett, MA Bittinger, EM Driggers, ... Nature 462 (7274), 739-744, 2009 | 4699 | 2009 |
| NF-κB as a therapeutic target in multiple myeloma T Hideshima, D Chauhan, P Richardson, C Mitsiades, N Mitsiades, ... Journal of Biological Chemistry 277 (19), 16639-16647, 2002 | 1183 | 2002 |
| Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma CM Annunziata, RE Davis, Y Demchenko, W Bellamy, A Gabrea, F Zhan, ... Cancer cell 12 (2), 115-130, 2007 | 1152 | 2007 |
| Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation F Wang, J Travins, B DeLaBarre, V Penard-Lacronique, S Schalm, ... Science 340 (6132), 622-626, 2013 | 953 | 2013 |
| Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations S Gross, RA Cairns, MD Minden, EM Driggers, MA Bittinger, HG Jang, ... The Journal of experimental medicine 207 (2), 339, 2010 | 888 | 2010 |
| Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis D Anastasiou, Y Yu, WJ Israelsen, JK Jiang, MB Boxer, BS Hong, ... Nature chemical biology 8 (10), 839-847, 2012 | 796 | 2012 |
| Validation of SMAP surface soil moisture products with core validation sites A Colliander, TJ Jackson, R Bindlish, S Chan, N Das, SB Kim, MH Cosh, ... Remote sensing of environment 191, 215-231, 2017 | 637 | 2017 |
| IDH mutations in cancer and progress toward development of targeted therapeutics L Dang, K Yen, EC Attar Annals of Oncology 27 (4), 599-608, 2016 | 526 | 2016 |
| IDH mutations in glioma and acute myeloid leukemia L Dang, S Jin, SM Su Trends in molecular medicine 16 (9), 387-397, 2010 | 464 | 2010 |
| Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling LT Lam, RE Davis, J Pierce, M Hepperle, Y Xu, M Hottelet, Y Nong, ... Clinical cancer research 11 (1), 28-40, 2005 | 440 | 2005 |
| AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations K Yen, J Travins, F Wang, MD David, E Artin, K Straley, A Padyana, ... Cancer discovery 7 (5), 478-493, 2017 | 437 | 2017 |
| Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma LT Lam, G Wright, RE Davis, G Lenz, P Farinha, L Dang, JW Chan, ... Blood, The Journal of the American Society of Hematology 111 (7), 3701-3713, 2008 | 413 | 2008 |
| Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers J Popovici-Muller, RM Lemieux, E Artin, JO Saunders, FG Salituro, ... ACS medicinal chemistry letters 9 (4), 300-305, 2018 | 405 | 2018 |
| MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma MA Milhollen, T Traore, J Adams-Duffy, MP Thomas, AJ Berger, L Dang, ... Blood, The Journal of the American Society of Hematology 116 (9), 1515-1523, 2010 | 342 | 2010 |
| Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo J Popovici-Muller, JO Saunders, FG Salituro, JM Travins, S Yan, F Zhao, ... ACS medicinal chemistry letters 3 (10), 850-855, 2012 | 247 | 2012 |
| Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development L Dang, SSM Su Annual review of biochemistry 86 (1), 305-331, 2017 | 206 | 2017 |
| Small molecule activation of PKM2 in cancer cells induces serine auxotrophy C Kung, J Hixon, S Choe, K Marks, S Gross, E Murphy, B DeLaBarre, ... Chemistry & biology 19 (9), 1187-1198, 2012 | 195 | 2012 |
| Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances … J Domingo-Domenech, C Oliva, A Rovira, J Codony-Servat, M Bosch, ... Clinical cancer research 12 (18), 5578-5586, 2006 | 195 | 2006 |
| MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo T Hideshima, P Neri, P Tassone, H Yasui, K Ishitsuka, N Raje, D Chauhan, ... Clinical cancer research 12 (19), 5887-5894, 2006 | 160 | 2006 |
| Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML S Choe, H Wang, CD DiNardo, EM Stein, S de Botton, GJ Roboz, ... Blood advances 4 (9), 1894-1905, 2020 | 154 | 2020 |
